- Home
- BOLD vs STTK Comparison
BOLD vs STTK Comparison
Compare BOLD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- STTK
- Stock Information
- Founded
- BOLD 2018
- STTK 2016
- Country
- BOLD United States
- STTK United States
- Employees
- BOLD N/A
- STTK N/A
- Industry
- BOLD
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- STTK Health Care
- Exchange
- BOLD Nasdaq
- STTK Nasdaq
- Market Cap
- BOLD 30.3M
- STTK 36.2M
- IPO Year
- BOLD 2024
- STTK 2020
- Fundamental
- Price
- BOLD $1.42
- STTK $0.77
- Analyst Decision
- BOLD Buy
- STTK Hold
- Analyst Count
- BOLD 3
- STTK 4
- Target Price
- BOLD $22.50
- STTK $3.00
- AVG Volume (30 Days)
- BOLD 69.6K
- STTK 301.6K
- Earning Date
- BOLD 05-12-2025
- STTK 05-01-2025
- Dividend Yield
- BOLD N/A
- STTK N/A
- EPS Growth
- BOLD N/A
- STTK N/A
- EPS
- BOLD N/A
- STTK N/A
- Revenue
- BOLD N/A
- STTK $5,721,000.00
- Revenue This Year
- BOLD N/A
- STTK N/A
- Revenue Next Year
- BOLD N/A
- STTK N/A
- P/E Ratio
- BOLD N/A
- STTK N/A
- Revenue Growth
- BOLD N/A
- STTK 245.26
- 52 Week Low
- BOLD $1.06
- STTK $0.69
- 52 Week High
- BOLD $12.65
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- STTK 40.89
- Support Level
- BOLD N/A
- STTK $0.85
- Resistance Level
- BOLD N/A
- STTK $0.95
- Average True Range (ATR)
- BOLD 0.00
- STTK 0.17
- MACD
- BOLD 0.00
- STTK -0.01
- Stochastic Oscillator
- BOLD 0.00
- STTK 10.15
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.